HUTCHMED (NASDAQ:HCM) announced that AstraZeneca (NASDAQ:AZN) submitted a U.S. regulatory application for ORPATHYS in combination with TAGRISSO for patients with MET-driven EGFR-mutated non-small cell lung cancer.
Evotec (NASDAQ:EVO) announced that Chief Scientific Officer Cord Dohrmann will step down from his role on September 30, 2026, by mutual consent.
Novo Nordisk (NYSE:NVO) agreed to license Hengrui Pharma’s phase 1-ready oral candidate HRS-1596 in a transaction valued at up to $2.6 billion.
Eli Lilly (NYSE:LLY) reported an indirect comparison suggesting that Foundayo 17.2 mg produced greater weight loss and A1C reduction than oral semaglutide 25 mg in adults with type 2 diabetes.
Psyence BioMed (NASDAQ:PBM) announced that its Texas subsidiary signed a binding term sheet with PsyLabs for proposed exclusive U.S. ibogaine rights.
Adicet Bio (NASDAQ:ACET) reported Phase 1 safety and efficacy data for prulacabtagene leucel (prula-cel) in patients with systemic lupus erythematosus with or without lupus nephritis.
BlossomHill Therapeutics (NASDAQ:BLSM) presented preclinical findings for BH-501284, an investigational pan-KRAS inhibitor, showing activity across KRAS-mutant cancer models.
Merck (NYSE:MRK) entered an exclusive global license agreement with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D inhibitor being developed for potential cancer treatments.
SCYNEXIS (NASDAQ:SCYX) secured a contract with the Biomedical Advanced Research and Development Authority to support development of SCY-247, with potential funding of up to approximately $214 million.
Arvinas (NASDAQ:ARVN) dosed the first participant in a Phase 1/2 trial of ARV-6723, an investigational oral immuno-oncology candidate designed to degrade HPK1 in adults with advanced solid tumors.
Cosmos Health (NASDAQ:COSM) reported more than $20 million in implied revenue from Cana Laboratories’ contract manufacturing pipeline, based on management estimates over the expected duration of agreements.
AbbVie (NYSE:ABBV) received U.S. Food and Drug Administration approval for JUVMO (tavapadon) tablets to treat adults with Parkinson’s disease.
